Corbus Pharmaceuticals Holdings Inc
(NASDAQ : CRBP)

( )
CRBP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.31%86.001.3%$1325.78m
AMGNAmgen Inc.
-0.93%201.981.2%$608.04m
GILDGilead Sciences, Inc.
-0.91%68.550.9%$534.22m
LOXOLoxo Oncology Inc
0.12%233.7812.7%$511.41m
BIIBBiogen Inc.
0.46%338.961.3%$413.85m
VRTXVertex Pharmaceuticals Incorporated
-0.42%193.881.9%$324.40m
ILMNIllumina, Inc.
-2.92%303.623.5%$304.88m
REGNRegeneron Pharmaceuticals, Inc.
-3.36%404.752.6%$294.14m
ALXNAlexion Pharmaceuticals, Inc.
-2.36%114.292.0%$213.93m
INCYIncyte Corporation
-1.39%77.332.5%$145.56m
AAgilent Technologies, Inc.
-0.89%71.291.5%$145.13m
EXASExact Sciences Corporation
-3.46%76.0725.3%$135.78m
SRPTSarepta Therapeutics, Inc.
-2.05%120.2815.4%$130.09m
LGNDLigand Pharmaceuticals Incorporated
-4.23%112.9123.1%$119.15m
NBIXNeurocrine Biosciences, Inc.
-0.27%91.285.1%$97.05m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.